Transforming Cancer Monitoring

At Oncobit, we aim to improve patient outcomes with high-precision and cutting-edge cancer monitoring solutions.

Our Mission

Enabling personalized cancer care

We use state-of-the-art technologies to develop cancer-specific monitoring tests and provide physicians with optimal therapy-decision support. Based on a simple blood sample, we offer innovative and robust solutions to closely, precisely and reliably monitor cancer and treatment response. This ensures that patients receive the best possible medical care at optimal cost efficiency.

Learn more about Oncobit

Our Solutions

Specific and sensitive tools for an optimal cancer therapy management

Our solutions provide clinicians with advanced molecular insights for precise cancer monitoring and therapy optimization.

Oncobit™ PM is a data-driven cancer monitoring platform for the sensitive and quantitative detection of specific cancer markers in circulating tumor-derived DNA (ctDNA) from the blood. It consists of cancer specific reagents and a cloud-based analysis software for automatic data interpretation and reporting. This ensures that clinicians receive an unbiased and clear report in a timely manner.

Learn more about our solutions

Our Journey


Exciting collaboration with the National Cancer Institute and Klaipeda University Hospital in Lithuania for the BIOMELKID study.

We are delighted to announce that Oncobit is collaborating with the National Cancer Institute (NCI) on the BIOMELKID trial. Our joint mission: To identify predictive and prognostic biomarkers in metastatic melanoma patients undergoing immunotherapy. Professor Vincas Urbonas and his team at the NCI are leading this impactful project focused on the study of ctDNA in melanoma patients. With our Oncobit PM digital PCR solutions, we are pleased to provide a powerful tool to reliably quantify ctDNA. Our shared goal is to unlock the secrets of circulating tumor DNA to better understand disease progression and treatment response. Aiming to improve patient care!

Oncobit among the top 3 finalists for the Swiss Excellence Product Awards 2023

Each year, the Swiss Excellence Foundation honors a Swiss start-up with the Swiss Excellence Award 2023 for an innovative product. The products are judged on their innovative content, their value creation potential and the quality of their business model and marketing concept. Oncobit is pleased to have made it to the finalists and congratulates Perovskia Solar AG for winning the award for its revolutionary and adaptable solar cells.

Read more

We exhibited at the 33rd Skin Cancer Congress and the ADO Annual Meeting in Hamburg

It was fantastic to experience the shared enthusiasm and determination to push the boundaries of melanoma care at the ADO meeting. In addition to receiving medical update on clinical trials, we have made significant progress with our projects on the monitoring of uveal melanoma with our Oncobit PM assays. We look forward to sharing more details of these developments in the near future.

Read more


Oncobit’s tests provide critical decision support in the treatment and monitoring of advanced melanoma patients.

Prof. Dr. med. Reinhard Dummer, Department of Dermatology USZ, Head of the Skin tumor center, Expert for the Comprehensive Cancer Center Zürich

Our Partners & Supporters